Polymer Capital Management HK LTD acquired a new stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 263,662 shares of the company's stock, valued at approximately $3,939,000. Polymer Capital Management HK LTD owned 0.31% of Corvus Pharmaceuticals as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently made changes to their positions in CRVS. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Corvus Pharmaceuticals by 26.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,629 shares of the company's stock worth $28,000 after purchasing an additional 748 shares during the period. ProShare Advisors LLC increased its stake in Corvus Pharmaceuticals by 7.7% during the 4th quarter. ProShare Advisors LLC now owns 13,764 shares of the company's stock worth $106,000 after acquiring an additional 979 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in Corvus Pharmaceuticals by 5.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 34,105 shares of the company's stock valued at $263,000 after acquiring an additional 1,696 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Corvus Pharmaceuticals by 6.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 32,232 shares of the company's stock valued at $238,000 after acquiring an additional 1,812 shares in the last quarter. Finally, Global Retirement Partners LLC bought a new stake in shares of Corvus Pharmaceuticals during the 2nd quarter valued at $30,000. Institutional investors and hedge funds own 46.64% of the company's stock.
Wall Street Analysts Forecast Growth
A number of brokerages recently commented on CRVS. Wall Street Zen cut Corvus Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, May 9th. Weiss Ratings upgraded shares of Corvus Pharmaceuticals from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, July 28th. Finally, LADENBURG THALM/SH SH upgraded shares of Corvus Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, July 30th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $33.33.
View Our Latest Report on Corvus Pharmaceuticals
Corvus Pharmaceuticals Price Performance
NASDAQ CRVS opened at $14.46 on Monday. The business has a fifty day moving average price of $14.06 and a two-hundred day moving average price of $14.86. Corvus Pharmaceuticals, Inc. has a fifty-two week low of $5.22 and a fifty-two week high of $26.95. The stock has a market capitalization of $1.22 billion, a PE ratio of -23.70 and a beta of 0.87.
Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.03). As a group, sell-side analysts expect that Corvus Pharmaceuticals, Inc. will post -0.79 earnings per share for the current year.
Insiders Place Their Bets
In other Corvus Pharmaceuticals news, Director David Scott Moore acquired 21,700 shares of Corvus Pharmaceuticals stock in a transaction that occurred on Thursday, June 11th. The shares were acquired at an average cost of $11.53 per share, with a total value of $250,201.00. Following the completion of the purchase, the director directly owned 21,700 shares of the company's stock, valued at $250,201. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 19.70% of the stock is owned by company insiders.
Corvus Pharmaceuticals Company Profile
(
Free Report)
Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company's research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.
Corvus's lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.
Recommended Stories
Want to see what other hedge funds are holding CRVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Corvus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corvus Pharmaceuticals wasn't on the list.
While Corvus Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
